Systematic review and meta-analysis of cannabis treatment for chronic pain

Pain Medicine

Volumn 10, Issue 8, 2009, Pages 1353-1368

  Martín Sánchez, Eva ^a   Furukawa, Toshiaki A ^d   Taylor, Julian ^b   Martin, Jose Luis R ^a,c  

^a Castile La Mancha Health Research Foundation FISCAM   (Spain)

^b Department of Experimental Neurology ^*  (Spain)

^c HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Cannabis; Chronic pain; Meta Analysis; Systematic review

Indexed keywords

CANNABIDIOL; CANNABIS; CODEINE; DRONABINOL; NABILONE; NITROGEN DERIVATIVE; PLACEBO; SECOBARBITAL; TETRAHYDROCANNABINOL;

ABDOMINAL PAIN; ARTICLE; ATAXIA; ATTENTION DISTURBANCE; BLURRED VISION; CHRONIC PAIN; CLINICAL TRIAL; COGNITION; CONFUSION; DIARRHEA; DISEASE SEVERITY; DISORIENTATION; DISSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; DYSPHORIA; EUPHORIA; HUMAN; INCREASED APPETITE; MEMORY DISORDER; META ANALYSIS; MOTOR PERFORMANCE; MYOCLONUS; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PSYCHOSIS; SIDE EFFECT; SPEECH DISORDER; SYSTEMATIC REVIEW; TASTE DISORDER; THOUGHT DISORDER; TINNITUS; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

ANALGESICS; CANNABINOIDS; CANNABIS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; PAIN, INTRACTABLE; PHYTOTHERAPY; RECEPTORS, CANNABINOID; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70949104601     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00703.x     Document Type: Article

References (54)

1. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003, 88(3):462-6.
2. Earleywine M. Understanding Marijuana. A New Look at the Scientific Evidence 2002, Oxford, Oxford University Press
3. Tramer MR, Carroll D, Campbell FA. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 2001, 323(7303):16-21.
4. Machado FC, Stéfano SC, De Cássia R, Rosa LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. Eur J Cancer Care 2008, 17(5):431-43.
5. Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 2001, 14:65-86.
6. Strasser F, Luftner D, Possinger K. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006, 24(21):3394-400.
7. Fisher B, Johnston D, Leake P. Marijuana for medicinal purposes: An evidence-based assessment. [Monograph on the internet]. 2002, http://www.worksafebc.com/health_care_providers/Assets/PDF/marijuana_medicinal_purposes.pdf, A research project sponsored by Medical Services. Workers' Compensation Board-Alberta Heritage Foundation, Available at: (accessed February 11, 2009
8. Grotenhermen F, Russo E. Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential 2002, Binghamton, Haworth Press
9. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986, 3:226. Classification of Chronic Pain
10. Pertwee RG. Cannabis and cannabinoids: Pharmacology and rationale for clinical use. Forsch Komplementarmed 1999, 6(3):12-15. suppl
11. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003, 2(5):291-8.
12. Campbell FA, Tramer MR, Carroll D. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001, 323(7303):13-16.
13. Martin CW. Efficacy of marijuana in treating chronic non cancer pain: A short review. [Monograph on the internet]. 2006, http://www.worksafebc.com/health_care_providers/Assets/PDF/marijuana_medicinal_purposes_update.pdf, WCD Evidence Based Practice Group, Available at: (accessed February 11, 2009
14. Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996, 17(1):1-12.
15. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323(7308):334-6.
16. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Wiley Series in Probability and Statistics 2000, Chichester, John Wiley & Sons, LTD
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-60.
18. Elbourne DR, Altman DG, Higgins JP. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol 2002, 31(1):140-9.
19. Review Manager (Rev Man) [Computer program] 2003, The Cochrane Collaboration, Version 4.2 for Windows, Oxford, England, Author
20. Sharp SJ, Sterne JAC. sbe16: Meta-analysis. Stata Technical Bulletin 1997, 38:9-14.
21. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004, 112(3):299-306.
22. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(1):50-2.
23. Jochimsen PR, Lawton RL, VerSteeg K, Noyes R. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Pharmacol Ther 1978, 24(2):223-7.
24. Killestein J, Hoogervorst EL, Reif M. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58(9):1404-7.
25. Notcutt W, Price M, Miller R. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 " N of 1" studies. Anaesthesia 2004, 59(5):440-52.
26. Noyes R, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975, 18(1):84-9.
27. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975, 15(2-3):139-43.
28. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65(6):812-19.
29. Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978, 23(4):397-401.
30. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329(7460):253.
31. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003, 17(1):21-9.
32. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004, 10(4):434-41.
33. Nurmikko TJ, Serpell MG, Hoggart B. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007, 133(1-3):210-20.
34. Wissel J, Haydn T, Muller J. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 2006, 253(10):1337-41.
35. Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: A randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. British Pain Society Edinburgh, Scotland, March 8-11, 2005
36. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008, 9(2):164-73.
37. Pinsger M, Schimetta W, Volc D. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-A randomized controlled trial. Wien Klin Wochenschr 2006, 118(11-12):327-35.
38. Karst M, Salim K, Burstein S. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. JAMA 2003, 290(13):1757-62.
39. Abrams DI, Jay CA, Shade SB. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007, 68(7):515-21.
40. Higgins JPT, Green S, Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. The Cochrane Library 2006, updated September 2006]. In, eds., Issue 4, Chichester, John Wiley & Sons, Ltd
41. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006, 40(2):251-60.
42. Jadad AR. Randomised Controlled Trials 1998, London, BMJ Books
43. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003, 42(4):327-60.
44. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett 2004, 25(1-2):14-23.
45. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006, 12(5):639-45.
46. Tomida I, zuara-Blanco A, House H. Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study. J Glaucoma 2006, 15(5):349-53.
47. Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth 1998, 81(1):77-84.
48. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007, 23(1):17-24.
49. van OJ, Bak M, Hanssen M. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002, 156(4):319-27.
50. Grech A, van OJ, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005, 20(4):349-53.
51. Yucel M, Solowij N, Respondek C. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008, 65(6):694-701.
52. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998, 352(9140):1611-16.
53. Walker P, Watanabe S, Taube A. The Edmonton Staging System. J Pain Symptom Manage 1996, 12(5):269.
54. Cancer Pain Relief 1986, World Health Organization, Geneva, WHO